Published on 27/12/2025
A Complete Guide to WHO GMP Compliance for Pharmaceutical Manufacturers
Good Manufacturing Practices (GMP) are the backbone of pharmaceutical quality assurance. The World Health Organization (WHO) sets global GMP standards through its technical reports, especially TRS 986 Annex 2. These guidelines ensure that pharmaceutical products are consistently produced and controlled to meet quality standards appropriate for their intended use.
WHO GMP compliance is crucial for manufacturers aiming to access international markets or participate in UN procurement tenders. This pillar article breaks down all key aspects of WHO GMP, including documentation, facility design, inspections, risk management, and how to maintain continuous compliance.
1. What is WHO GMP Compliance?
WHO GMP compliance means aligning manufacturing operations with the standards published by WHO under its Technical Report Series (TRS), particularly Annex 2 of TRS 986. These cover manufacturing, quality control, storage, distribution, and documentation practices.
WHO GMP applies to manufacturers of:
Explore the full topic: REGULATORY COMPLIANCE
- Finished Pharmaceutical Products (FPPs)
- Active Pharmaceutical Ingredients (APIs)
- Vaccines and Biologicals
- Herbal and Traditional Medicines
Compliance ensures that drugs are consistently high in quality, safe for human use, and effective for their indicated purposes.
2. Importance of WHO GMP for Global Supply
Many countries, especially low- and middle-income ones, use WHO GMP as a
- Eligibility to apply for WHO Prequalification
- Credibility in global supply chains
- Access to tenders from agencies like UNICEF, UNDP, and Global Fund
- Faster approvals via collaborative registration pathways
As per USFDA standards, many GMP principles overlap, but WHO GMP is particularly suited for emerging market needs and flexible implementation frameworks.
3. Key Elements of WHO GMP Compliance
3.1 Quality Management System (QMS)
A robust QMS forms the foundation of GMP compliance. It must include:
- Quality Manual and Policy
- Documented SOPs and batch records
- Change control and deviation systems
- CAPA procedures
- Annual product quality review (APQR)
Use templates from Pharma SOP to implement standardized documentation practices aligned with WHO expectations.
3.2 Personnel and Training
Qualified personnel must be employed, with well-defined roles and responsibilities. Training is mandatory for:
- GMP principles
- Hygiene and gowning
- Equipment usage
- Deviation and incident reporting
Training should be evaluated periodically and documented for audits.
3.3 Premises and Equipment
WHO GMP requires that the premises be:
- Well ventilated and illuminated
- Logically designed to prevent cross-contamination
- Equipped with cleanable surfaces and pest-proofing
All equipment must be qualified (IQ, OQ, PQ), calibrated, and maintained per schedule. Refer to Pharma Validation for qualification protocols.
3.4 Documentation and Record Keeping
Documentation should be clear, legible, and contemporaneous. Key GMP documents include:
- Master Manufacturing Records (MMRs)
- Batch Manufacturing Records (BMRs)
- Standard Operating Procedures (SOPs)
- Logbooks for equipment and utilities
Ensure data integrity by following ALCOA+ principles as outlined in Pharma GMP.
4. WHO GMP Inspections
WHO conducts on-site GMP inspections as part of its prequalification program or upon request by NRAs. Areas typically covered include:
- Production operations
- Quality control labs
- Warehousing and material handling
- Utility systems (HVAC, WFI, compressed air)
- Documentation systems
Prepare for inspections with internal audits and mock drills. WHO publishes inspection reports and common deficiencies online for learning.
5. Validation Requirements under WHO GMP
Process validation is essential to demonstrate consistent output. Types of validation include:
- Cleaning Validation
- Equipment Qualification (IQ/OQ/PQ)
- Analytical Method Validation
- Computer System Validation (CSV)
Validation protocols must define acceptance criteria, critical parameters, and control limits. Refer to Stability Studies for long-term data requirements.
6. Risk-Based GMP Approach
WHO GMP emphasizes a risk-based approach aligned with ICH Q9. This includes:
- Hazard identification for critical processes
- FMEA or HACCP for risk assessment
- Mitigation strategies for CPPs and CQAs
Maintain a risk register and update it regularly. Risk management should be integrated into every SOP and protocol.
7. Cleaning and Hygiene Control
Cleaning procedures should be validated and documented. Key points:
- Establish cleaning frequencies for rooms and equipment
- Validate cleaning effectiveness using swab/rinse tests
- Set residue limits based on toxicity and batch size
- Control contamination sources through proper gowning
Microbiological monitoring is essential in sterile and non-sterile areas. Refer to Clinical Studies for environmental monitoring SOPs.
8. Handling Deviations, CAPA, and Change Control
WHO GMP requires robust systems for handling unexpected events. These include:
- Deviation reporting with root cause analysis (RCA)
- CAPA plans with timelines and responsibilities
- Change control for processes, materials, and equipment
All changes must be approved by QA and risk-assessed for impact on product quality and regulatory filings.
9. Continuous Improvement and Self-Inspection
GMP compliance is not a one-time activity. Self-inspections must be scheduled quarterly or biannually and must evaluate:
- SOP compliance
- Documentation accuracy
- Training effectiveness
- Facility cleanliness
Audit outcomes should lead to CAPAs and drive continuous improvement. You can access checklists and audit templates at Pharma Regulatory.
10. WHO GMP vs Other Global Standards
While WHO GMP shares many principles with USFDA, EMA, and PIC/S guidelines, it differs in:
- More flexibility for low-resource settings
- Greater emphasis on documentation and quality risk management
- Specific applicability to prequalification of products
WHO GMP is especially useful for manufacturers in Africa, Asia, and Latin America seeking market entry in countries relying on WHO oversight.
11. Conclusion
WHO GMP compliance is essential for any pharmaceutical facility aiming for global credibility and market access. From infrastructure design to risk assessment, every detail matters. Establishing a quality culture, training personnel, and preparing for audits ensures consistent success and inspection readiness.
Stay updated with the latest WHO GMP changes by subscribing to WHO TRS publications and accessing industry resources from Pharma Validation.